Boeing to cut 17,000 jobs as losses deepen during factory strike

Boeing to cut 17,000 jobs as losses deepen during factory strike


Boeing 737 MAX airliners are pictured at the company’s factory on Thursday, Sept. 12, 2024, in Renton, Wash.

Stephen Brashear | AP

Boeing will cut 10% of its workforce, or about 17,000 people, as the company’s losses mount and a machinist strike that has idled its aircraft factories enters its fifth week. It will also delay the launch of its new wide-body airplane.

The manufacturer won’t deliver its still-uncertified 777X wide-body plane until 2026, putting it some six years behind schedule, and will stop making commercial 767 freighters in 2027 after it fulfills remaining orders, CEO Kelly Ortberg said in a staff memo on Friday afternoon.

Boeing expects to report a loss of an $9.97 a share in the third quarter, the company said in a surprise release on Friday. It expects to report a pretax charge of $3 billion in commercial airplane unit and $2 billion for its defense business.

In preliminary financial results, Boeing said it expects to have an operating cash outflow of $1.3 billion for the third quarter.

“Our business is in a difficult position, and it is hard to overstate the challenges we face together,” Ortberg said. “Beyond navigating our current environment, restoring our company requires tough decisions and we will have to make structural changes to ensure we can stay competitive and deliver for our customers over the long term.”

The job and cost cuts are the most dramatic moves to date from Ortberg, who is just over two months into his tenure in the top job.

He was tasked with restoring Boeing after safety and manufacturing crises, but the labor strike has been the biggest challenge yet for Ortberg. Credit ratings agencies have warned the company is at risk of losing its investment-grade rating, and Boeing has been burning through cash in what company leaders hoped would be a turnaround year.

S&P Global Ratings said earlier this week that Boeing is losing more than $1 billion a month from the strike, which began Sept. 13 after machinists overwhelmingly voted down a tentative agreement the company reached with the union. Tensions have been rising between the manufacturer and the union, and Boeing withdrew a contract offer earlier this week.

On Thursday, Boeing said it filed an unfair labor practice charge with the National Labor Relations Board that accused the International Association of Machinists and Aerospace Workers of negotiating in bad faith and misrepresenting the planemakers’ proposals. The union had blasted Boeing for a sweetened offer that it argued wasn’t negotiated with the union and said workers wouldn’t vote on it.

The job cuts, which Ortberg said would occur “over the coming months,” would hit just after Boeing and its hundreds of suppliers have been scrambling to staff up in the wake of the pandemic, when demand cratered.



Source

Inside the booming business of wellness third spaces and membership clubs
Business

Inside the booming business of wellness third spaces and membership clubs

A few years ago, Grace Guo began to crave places in New York City where hanging out with friends didn’t have to involve alcohol. Newly sober and surrounded by friends who also chose not to drink, Guo said she wanted alternatives to the typical social scene. After some research, she landed on Bathhouse and Othership: […]

Read More
FDA vaccine head will step down in April after string of controversial decisions
Business

FDA vaccine head will step down in April after string of controversial decisions

The logo for the Food and Drug Administration is seen ahead of a news conference at the Health and Human Services Headquarters in Washington, DC on April 22, 2025. Nathan Posner | Anadolu | Getty Images A key U.S. Food and Drug Administration official who oversees vaccines and biotech treatments will step down from the […]

Read More
FDA reversals leave investors worrying about the fates of other experimental drugs
Business

FDA reversals leave investors worrying about the fates of other experimental drugs

Investors are concerned about the fates of multiple experimental drugs for hard-to-treat diseases following a string of recent rejections from the U.S. Food and Drug Administration.  The FDA in the past year has denied or discouraged the applications of at least eight drugs, according to RTW Investments, including a gene therapy for Huntington’s disease from […]

Read More